What should men know about prostate-specific antigen screening before giving informed consent?

American Journal of Medicine

Volumn 105, Issue 4, 1998, Pages 266-274

  Chan, Evelyn C Y ^a   Sulmasy, Daniel P ^b,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c ST VINCENT S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CONSERVATIVE TREATMENT; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; INFORMED CONSENT; LIFE EXPECTANCY; MEDICAL PRACTICE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUESTIONNAIRE;

EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH; PROFESSIONAL PATIENT RELATIONSHIP;

DELPHI TECHNIQUE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0032191073     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00257-5     Document Type: Article

References (39)

1. 1. Woolf SH. Screening for prostate cancer with prostate-specific antigen - an examination of the evidence. NEJM. 1995;333:1401-1405.
2. 2. Early Detection of Prostate Cancer. American Urological Association Executive Committee Report. Baltimore, Md: American Urological Association; May 1992.
3. 3. Mettlin C, Jones G, Averett H, et al. Defining and updating the American Cancer Society guidelines for the cancer-related checkup. CA: Cancer Clin J. 1993;43:42-46.
4. 4. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
5. 5. Physician Data Query [computer database]. Prostate cancer screening state-of-the-art statement. Bethesda, Md: National Cancer Institute; 1996.
6. 6. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. J Urol. 1994;152: 1905-1909.
7. 7. Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993; 119:914-923.
8. 8. Wilt T, Brawer MK. The prostate cancer intervention versus observation trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol. 1994;152:1910-1914.
9. 9. American College of Physicians. Clinical guideline: screening for prostate cancer. Ann Intern Med. 1997;126:480-484.
10. 10. Glode ML. Prostate cancer screening: a place for informed consent? Hosp Pract. 1994;September 15;29(9):8-12.
11. 11. Brett AS. The mammography and prostate-specific antigen controversies: implications for patient-physician encounters and public policy. J Gen Intern Med. 1995;10:266-270.
12. 12. Hahn DL, Roberts RG. PSA screening for asymptomatic prostate cancer: truth in advertising. J Fam Pract. 1993;37:432-435.
13. 13. Marshall KG. Screening for prostate cancer: how can patients give informed consent? Can Fam Phys. 1993;39:2385-2390.
14. 14. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Press; 1994:120-188.
15. 15. Faden RR, Beauchamp TL. A History and Theory of Informed Consent. New York: Oxford University Press; 1986.
16. 16. Sprung CL, Winick BJ. Informed consent in theory and practice: legal and medical perspectives on the informed consent doctrine and a proposed reconceptualization. Crit Care Med. 1989;17:1346-1354.
17. 17. Sulmasy DP, Lehmann LS, Levine DM, Faden RR. Patient's perceptions of the quality of informed consent for common medical procedures. J Clin Ethics. 1994;5:189-194.
18. 18. White C, Mason A, Feehan M, Templeton PA. Informed consent for percutaneous lung biopsy: comparison of two consent protocols based on patient recall after the procedure. Am J Roentgenol. 1995; 165:1139-1142.
19. 19. Lidz CW, Meisel A, Holden JL, et al. Informed consent and the structure of medical care. In: President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Making Health Care Decisions. Volume II. Appendices. Empirical studies of informed consent. Washington, DC: US Government Printing Office; 1982:317-410.
20. 20. Stanley B, Guido J, Stanley M, DiAnn S. The elderly patient and informed consent: empirical findings. JAMA. 1984;252:1302-1306.
21. 21. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA. 1997;277:1467-1474.
22. 22. Delbecq AL, Van de Ven AH, Gustafson DH. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes. Middleton, Wisconsin: Green Briar Press; 1986.
23. 23. Health Promotion for Men 50+. Washington, DC: American Association of Retired Persons; 1994.
24. 24. Rubenstein L. Strategies to overcome barriers to early detection of cancer among older adults. Cancer. 1994;74:2190-2193.
25. 25. Stair J. Public awareness of screening programs. Oncol Nurs Forum. 1992;19:93-94.
26. 26. Mainous AG III, Hagen MD. Public awareness of prostate cancer and the prostate specific antigen test. Cancer Pract. 1994;2:217-221.
27. 27. Flood AB, Wennberg JE, Nease RF, et al. The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med. 1996;11:342-349.
28. 28. Jaroff L. The man's cancer. Time. 1996;April 1:58-65.
29. 29. Grove A. Taking on prostate cancer. Fortune. 1996;May 13:55-72.
30. 30. Stipp D. The gender gap in cancer research. Fortune. 1996;May 13:74-76.
31. 31. McCoy CB, Anwyl RS, Metsch LR, et al. Prostate cancer in Florida: knowledge, attitudes, practices and beliefs. Cancer Pract. 1995;3: 88-93.
32. 32. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test: what do patients know? J Cancer Educ. 1996;11:39-44.
33. 33. Denmark-Wahnefried W, Strigo T, Catoe K, et al. Knowledge, beliefs and prior screening behavior among blacks and whites report-ing for prostate cancer screening. Urology. 1995;46:346-3451.
34. 34. Wolf AMD, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med. 1996;156:1333-1336.
35. 35. Wolf AMD, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell out patients? Am J Med. 1997;103:308-314.
36. 36. Ingelfinger FJ. Informed (but uneducated) consent. NEJM. 1972: 287:465-466.
37. 37. Marshall KG. Informed consent for tests for prostate cancer. JAMA. 1995;274:127-128. Letter.
38. 38. Lidz CW, Appelbaum PS, Meisel JD. Two models of implementing informed consent. Arch Intern Med. 1998;148:1385-1389.
39. 39. Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial apc gene testing for familial adenomatous polyposis. NEJM. 1997;336:823-827.